Q-omics provides the consensus-scored BRD3OS profile across patient tissues and cancer cell-line models. BRD3OS expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BRD3OS is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, BRD3OS RNA expression shows 19,595 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where BRD3OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD3OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD3OS survival associations across molecular data types. BRD3OS RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD3OS RNA expression–survival associations across cancer types. High BRD3OS expression shows unfavorable associations in BLCA, KICH, ACC and LUSC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BRD3OS RNA expression.
This table summarizes BRD3OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BRD3OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD3OS shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, COAD and BRCA. The HNSC box plot shows higher BRD3OS RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with BRD3OS in patient tissues and cancer cell lines. In patient samples, BRD3OS shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BRD3OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS.
